FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

247 letters match. Newest first.

  1. Sovereign Pharmaceuticals, LLC

    FDA cited Sovereign Pharmaceuticals for manufacturing failures in bulk tablets, inadequate out-of-specification (OOS) investigations, quality-unit lapses, and an unapproved biological product.

    High risk
  2. American Cleaning Solutions

    FDA warned American Cleaning Solutions after a 2022 inspection found hand sanitizer made with inadequate cleaning, unvalidated processes, and substituted ethanol.

    High risk
  3. Eksa Mills S.A. de C.V.

    FDA cited Eksa Mills for CGMP violations, including shared-equipment contamination risks, after an April 2022 inspection of its Mexican drug facility.

    High risk
  4. Sanitizer Supply LLC

    FDA warns Sanitizer Supply LLC that its hand sanitizer wipes and sanitizers lacked required potency and microbial testing before release.

    High risk
  5. Episciences Inc.

    FDA warns Episciences Inc. that its Boise, Idaho plant made OTC drugs without adequate batch testing, process validation and failure investigations.

    High risk
  6. Verde Cosmetic Labs LLC

    FDA warned Verde Cosmetic Labs after an inspection found inadequate CGMP controls for OTC topical drugs, including cleaning and water system failures.

    High risk
  7. Vitti Labs, LLC

    FDA warns Vitti Labs over unapproved umbilical cord and amniotic membrane products and sterile manufacturing failures.

    High risk
  8. DSP Skin Care LLC

    FDA cites DSP Skin Care for manufacturing failures and unapproved, misbranded Hongosan antifungal drugs.

    High risk
  9. Custom Research Labs Inc.

    FDA warned Custom Research Labs Inc. about manufacturing-practice violations and unapproved, misbranded OTC drugs, including hand sanitizers and topical analgesics.

    High risk
  10. Bi-Coastal Pharma International

    FDA warned Bi-Coastal Pharma International about adulterated drugs due to poor complaint handling, quality-unit oversight, batch release, and training.

    High risk
  11. Bioiberica, SAU

    FDA warned Bioiberica over unvalidated rework and missing stability testing of API batches at its Spain plant.

    High risk
  12. Genlabs Corporation

    FDA warns Genlabs Corporation of Chino, California, that its OTC hand soaps are adulterated and misbranded after finding serious CGMP failures.

    High risk
  13. Mirfeel Korea Co., Ltd.

    Mirfeel Korea's hand sanitizer contained benzene and had testing failures; FDA also says food-pouch packaging misbranded.

    High risk
  14. Monarch PCM, LLC

    Monarch PCM, LLC made unapproved skin drugs and broke manufacturing rules, with microbial contamination and weak investigations.

    High risk
  15. Re-Gen Active Lab, Inc.

    FDA warned Re-Gen Active Lab over unapproved amniotic/umbilical cord injectables and serious sterility failures.

    High risk
  16. Colorful Products Corporation

    FDA warned Colorful Products Corporation about serious current good manufacturing practice (CGMP) failures for its over-the-counter topical drugs and hand sanitizers.

    High risk
  17. The W.S. Badger Company, Inc.

    FDA warned W.S. Badger over repeat manufacturing-quality failures in OTC drug products, including sunscreen process, cleaning, test-method, and OOS investigation problems.

    High risk
  18. Guangzhou Zhongkebaishi Health Industry Co., Ltd.

    Guangzhou Zhongkebaishi's Hand Sanitizer Gel, labeled 75% ethanol, tested at 51% and was refused US import.

    High risk
  19. Ultra Seal Corporation

    FDA warns Ultra Seal and ULTRAtab over manufacturing quality failures in over-the-counter drug cleaning, testing, and release.

    High risk
  20. Yusef Manufacturing Laboratories, LLC

    FDA warned Yusef Manufacturing Laboratories over serious CGMP violations in its OTC drugs and hand sanitizers, including untested ethanol.

    High risk
  21. NDAL Mfg Inc.

    NDAL Mfg's honey nasal sprays had manufacturing-rule violations, microbial contamination, and lacked FDA approval as new drugs.

    High risk
  22. Agropharma Laboratories, Inc.

    FDA cited Agropharma Laboratories in Salinas, Puerto Rico, for serious manufacturing violations affecting its OTC antiseptics and hand sanitizers.

    High risk
  23. Accu Bio-Chem Laboratories

    FDA warned Accu Bio-Chem Laboratories, a contract OTC drug-testing lab, over inadequate failing-result investigations, method verification, and data controls.

    Medium
  24. CardioQuip, LLC

    CardioQuip sold significantly modified cardiac heater-cooler devices without required FDA clearance and with quality system violations.

    High risk
  25. Indiana Chem-Port

    Indiana Chem-Port API manufacturer cited for CGMP deviations including dirty equipment, unvalidated processes, and cleaning failures.

    High risk
  26. Health Plus Inc.

    FDA warned Health Plus Inc. over manufacturing quality failures in its Super Colon Cleanse laxative made in Chino, California.

    High risk
  27. Cosmo Bio Co., Ltd.

    FDA cited South Korea's Cosmo Bio for CGMP failures and for selling an unapproved, misbranded acne drug serum in the U.S.

    High risk
  28. Hubei Kangzheng Pharmaceutical Co., Ltd.

    FDA warns Hubei Kangzheng over non-sterile ophthalmic drops, CGMP failures, and unapproved/misbranded pi yen chin.

    High risk
  29. Sanitor Corporation

    Sanitor Corporation was cited for CGMP violations after hand sanitizer failed microbial testing and skin-bleaching drugs were sold without approval.

    High risk
  30. Surgenex LLC

    FDA warned Surgenex it sold unapproved umbilical cord and amniotic membrane products for injection without a biologics license and with serious manufacturing problems.

    High risk
  31. Matthew 7:25 Inc dba Thrive Pharmacy

    FDA says Thrive Pharmacy compounded drugs without valid prescriptions and released subpotent buprenorphine troches, making them adulterated and misbranded.

    High risk
  32. Marcus Research Laboratory, Inc.

    FDA warned Marcus Research Laboratory after a May 2021 inspection found it released povidone iodine API made after reactor fires and smoke without fully testing for contamination.

    High risk
  33. Laboratorio Pharma International SRL

    FDA warns Laboratorio Pharma International over CGMP failures, unapproved GELAZUL, misbranding, and incomplete beta-lactam separation.

    High risk
  34. Furley Bioextracts SDN BHD

    FDA warns Furley Bioextracts over manufacturing failures and unapproved PainFix Relief Gel for the U.S. market.

    High risk
  35. Gulsah Uretim Kozmetik Sanayi Anonim Sirketi

    Turkish OTC drug maker Gulsah failed to test its products and ingredients, and FDA blocked its U.S. imports.

    High risk
  36. Natural Beauty Care Pty Ltd

    FDA warned Natural Beauty Care Pty Ltd that its OTC drugs are adulterated due to CGMP failures and no finished-product or ingredient testing.

    High risk
  37. Utah Cord Bank LLC dba Utah Cell Bank

    Utah Cell Bank made unapproved injectable stem cell products and fell short on sterility and manufacturing controls, FDA found.

    High risk
  38. Maitland Labs of Central Florida

    FDA warns Maitland Labs of Central Florida over sterile compounded drugs with manufacturing quality failures, mislabeling, and unapproved new drug violations.

    High risk
  39. BBC Group Limited

    FDA cites BBC Group Limited for data integrity, lab, equipment failures and unapproved, misbranded hand sanitizers.

    High risk
  40. Sanit Technologies, LLC dba Durisan

    FDA says Sanit Technologies (Durisan) released contaminated alcohol-free hand sanitizer, including Burkholderia cepacia, made with contaminated water.

    High risk
  41. Syntec Pharma Corp

    FDA warned Syntec Pharma Corp, an API repackager in Farmingdale, New York, that weak cross-contamination controls and quality oversight made its drugs adulterated.

    High risk
  42. Biotek India

    Biotek India, an OTC drug maker, lacked active-ingredient testing and sold an unapproved 99% isopropyl rubbing alcohol.

    High risk
  43. BioLyte Laboratories, LLC

    FDA cited BioLyte Laboratories for manufacturing failures and unapproved silver, CBD, and magnesium drug products.

    High risk
  44. Dibar Nutricional S. de R.L. de C.V.

    Dibar Nutricional's OTC drugs drew FDA CGMP violations and an import alert over missing testing.

    High risk
  45. Foshan Biours Biosciences Co., Ltd.

    Foshan Biours Biosciences, an OTC patch maker, lacked release testing, cleaning validation, and stability data, so FDA says its drugs are adulterated.

    High risk
  46. Allay Pharmaceuticals, LLC

    FDA warned Allay Pharmaceuticals over CGMP failures and sub-potent tablets, and distribution of an unapproved biological product.

    High risk
  47. Yuyao YiJia Daily Chemical Co., Ltd.

    Yuyao YiJia, a Chinese OTC drug and hand sanitizer maker, lacked finished-product, component and stability testing and an adequate quality unit.

    High risk